The global mild cognitive impairment market size is projected to be worth USD 2.96 billion by 2030, registering a CAGR of 5.30% during the forecast period (2022 - 2030)
Mild cognitive impairment (MCI) is a stage of memory loss or other cognitive skill loss (such as language or visual/spatial perception) in people who can still perform most everyday tasks independently. MCI can develop from a variety of causes, and those who have it may acquire dementia. MCI is a stage on the illness continuum for neurodegenerative disorders such as Alzheimer's. MCI can recover to normal cognition or remain stable in some people. The Dementia market has been segmented based on disease type, age, Indications, treatment, and region. The market is driven by factors like the increasing geriatric population globally and rising awareness about mild cognitive impairment. However, the unavailability of specific treatment could hamper the growth of the mild cognitive impairment market.
Mild Cognitive Impairment Market COVID-19 Analysis
COVID-19 has put significant strain on dementia health and social care systems across the world. As a result, services, assistance for people suffering from MCI have been reduced due to restrictions set to curb the spread of the virus. The pandemic has also caused delays in the provision of mental health services and increased the need for digital intervention. Such consequences have boosted the need for efficient remote care for mild cognitive impairment (Dementia) to compensate for the pandemic's disruptions.
According to the National Library of Medicine, the dementia population is at significant risk of getting COVID-19 infection because cognitive problems make it hard to follow the safety precautions designed to limit viral transmission. As a result, the pandemic had a detrimental impact on the market's growth potential for moderate cognitive impairment (Dementia).
Dementia Market Dynamics
Value Chain Analysis
The value chain analysis for the market comprises four major components, which start with the research and product development stage where the new techniques and research are undertaken to make the products better and unique, followed by the manufacturing, in this stage, the product strategies are ready, and the manufacturing process of the product starts, distribution & sales where distribution includes intermediaries, direct selling, online channels, and others. For this, the company's marketing and sales strategies play a crucial role in understanding the characteristics of the industry in which one is competing It ends with post-sales monitoring, many companies undertake numerous surveys to get post-sale feedback in order to ascertain the advantages and disadvantages of genetic testing.
Dementia Market Segment Overview
By Disease Type
Amnestic MCI is a condition where people have memory impairments that are worse than average for their age and educational level but not severe enough to affect daily life. People who have amnestic MCI may begin to forget important information that they would have previously easily recalled, such as appointments, conversations, and recent events.
Amnestic MCI held the largest share in the Dementia market in 2021 due to the increase in the older population across the globe.
Non-amnestic MCI affects thinking skills other than memory, including the ability to make sound decisions, judge the time or sequence of steps needed to complete a complex task, or visual perception. Furthermore, those with non-amnestic MCI are more likely to develop vascular dementia, frontotemporal dementia, or dementia with lewy bodies.
Childhood MCI is a mental disorder, since it develops as a variety of symptoms, this condition cannot be classified as a disease. Moreover, cognitive deficiencies (intellectual disability) appear in children as substantial limitations in their abilities to learn and perform.
Mental impairment in older adults refers to a person's concern about or difficulties with thinking, memory, concentration, and other brain functions that exceeds what is normally expected with ageing. Additionally, adult-onset conditions such as: Brain or spinal cord damage, vitamin deficiency, or drug or alcohol misuse. Furthermore, Subjective cognitive decline (SCD) affects 11.1 % of individuals, or 1 in 9, and mild memory loss is rather common, affecting between 10% and 20% of older persons in the United States.
Mild cognitive impairment (MCI) is a prevalent problem among the elderly. It is distinguished by a decline in memory, attention, and cognitive function that exceeds what would be predicted based on age and educational level. MCI has no substantial impact on people's daily activities.
The geriatric segment held the largest market share in 2021 due to a surge in vulnerable older people population across the globe.
Lewy body dementia (LBD) is one of the most frequent kinds of dementia. It mainly affects adults over the age of 50. People with LBD frequently act out their dreams and make violent gestures while sleeping. It is known as REM sleep behavior disorder. It is sometimes the first indication that someone has LBD. According to the Lewy Body Dementia Association, more than one million persons in the U.S have Lewy body dementia.
Parkinson's disease dementia (PDD) is a loss in thinking and reasoning capacity that occurs at least a year after diagnosis in certain Parkinson's patients. Parkinson's disease is caused by alterations in the brain's movement-related area, which causes early symptoms such as tremors and shakiness, muscular rigidity, a shuffling stride, stooped posture, trouble commencing movement, and a lack of facial expression.
Alzheimer's disease is the most prevalent kind of dementia and a degenerative brain illness. It currently affects an estimated 6.2 million Americans aged 65 and older. If no medical advances are achieved to prevent, slow, or cure Alzheimer's disease, this amount might climb to 13.8 million by 2060. According to official death certificates, Alzheimer's disease was the sixth-leading cause of death in the United States in 2019, and the fifth-leading cause of death among Americans 65 and over.
This segment held the largest share in 2021, owning to the growing number of people living with Alzheimer’s dementia across the globe.
Vascular dementia is the second most frequent kind of dementia, accounting for 17-30% of cases. It is frequently caused by a blood artery obstruction, such as in a stroke, or by a brain injury that results in patches of dead tissue or bleeding. Vascular dementia alone affects 5% to 10% of dementia sufferers. Despite its prevalence, many professionals believe that vascular dementia, like Alzheimer's disease, is underdiagnosed. Furthermore, like Alzheimer's disease, vascular dementia worsens with age, contributing to the global dementia epidemic in ageing populations.
Other indications comprise mixed dementia, Huntington's disease, limb-predominant age-related TDP-43 encephalopathy, and chronic traumatic encephalopathy.
Based on treatment type, the mild cognitive impairment (MCI) treatment market is segmented into medication and therapy. Medication segment held the largest share in 2021. This is due to its immediate and effective impact on MCI symptoms. Medicine has been further categorized into cholinesterase inhibitors, benzodiazepines, glutamate inhibitors, antihistamines, Mao inhibitors, and proton pump inhibitors.
Based on therapy type, the Mild Cognitive Impairment Market is segmented into Cognitive Stimulation Therapy, Cognitive Behavioral Therapy (CBT). Cognitive Stimulation Therapy (CST) is a well-known therapy for people with mild to severe dementia. CST therapy can be given by anyone who works with dementia patients, including caregivers, psychologists, occupational therapists, and nurses. CST sessions can take place in a range of locations, such as nursing homes, hospitals, and daycare facilities. The UK Government's NICE dementia advice also suggests group cognitive stimulation therapy for patients with mild to severe dementia. CST is widely used in the UK and throughout the world, with initiatives in at least 35 countries.
Mild Cognitive Impairment Market Regional Analysis
The Mild Cognitive Impairment Market based on the region has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The rising burden of cognitive impairment and increasing geriatric population is one of the major factors driving the market growth. The growth Dementia market can be attributed to factors such as the increasing prevalence of mild cognitive impairment, rising geriatric population, and growing awareness about available therapies for mild cognitive impairment.
The increase in the older patient population, ongoing research to find the effective cure are fueling the growth of the North American Mild Cognitive Impairment Market.
In the US, more than 16 million people have cognitive impairment. Alzheimer's disease, the most well-known kind of cognitive impairment, affects an estimated 5.1 million Americans aged 65 and older; this is expected to climb to 13.5 million by 2050. Such a higher prevalence of the disease is anticipated to bolster the demand for mild cognitive impairment (dementia) drugs among the patient population over the coming years. Furthermore, a number of market participants are working to implement strategic developments that will aid in market expansion. As an instance, the US Food and Drug Administration approved Aduhelm (aducanumab) to treat Alzheimer's disease in June 2021, which is expected to show some effect MCI. As a result of the developments, as well as the disease's increasing burden, the regional market is expected to grow significantly over the forecast period.
Dementia Market Competitive Landscape
The industry players are adopting several business strategies to increase their market presence. They are significantly investing in R&D activities to expand their product portfolio, further driving the Mild Cognitive Impairment Market. In addition, the market players are adopting several strategic initiatives such as new product launches, contractual agreements, mergers & acquisitions, increasing investments, and partnering with other players to expand their global footprint.
Some key players in the market are Pfizer Inc. (US), Novartis AG (Switzerland), and F. Hoffman La Roche Ltd (Switzerland). Pfizer, Inc. (Pfizer) is one of the leading research-based biopharmaceutical organizations. The company develops medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer additionally teams up with healthcare providers, governments, and local communities to support and expand access to reliable and affordable healthcare worldwide. It operates in Germany, France, Greece, South Korea, Mexico, Russia, the Netherlands, India, Poland, Turkey, Israel, and China. The company has R&D platforms in biosimilars, gene therapy, precision medicines, and medicinal sciences. Its products serve key therapeutic areas, such as oncology, internal medicine, inflammation and immunology, rare diseases, and vaccines, along with contract manufacturing capabilities. Pfizer Centre One, a part of Pfizer, focuses on custom APIs, sterile injectables, and highly potent oral solid dosage forms. Product launcehs such as The FDA approval of Novartis AG's (Switzerland) Rivastigmine (Exelon) for mild-to-moderate Alzheimer’s disease and mild-to-moderate dementia associated with Parkinson's disease in June 2019 are also driving market grwoth.
List of companies covered in this report:
Mild Cognitive Impairment Market Recent Developments
Mild Cognitive Impairment Market Report Overview
The study covers the existing short-term and long-term market effects. It helps decision-makers to draught short-term and long-term business plans by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market.
Global Mild Cognitive Impairment Market, By Disease Type
Global Dementia market, By Age
Global Mild Cognitive Impairment Market, By Indications
Global Mild Cognitive Impairment Market, By Treatment
Global Mild Cognitive Impairment Market, By Region
|Market Size||USD 2.96 billion|
|Historical Data||2018 & 2020|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Disease Type, Age, Indications, Treatment|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World|
|Key Vendors||• Pfizer Inc. (US) • F. Hoffman La Roche Ltd (Switzerland) • Novartis AG (Switzerland) • Accord UK Ltd (UK) • Dr. Reddy’s laboratories Ltd (India) • Hikma Pharmaceuticals PLC (UK) • Sun Pharmaceuticals ltd (India) • Johnson & Johnson Services, Inc. (US) • Teva Pharmaceutical Industries Ltd., (Israel) • Takeda Pharmaceutical Company Limited (US)|
|Key Market Opportunities||Promoting patient mental health programs|
|Key Market Drivers||• Increasing geriatric population • Rising awareness about mild cognitive impairment|